

Effectiveness of Diet Recommendations for Laryngopharyngeal Reflux Disease: A Systematic Review for Clinical Practice and Studies[☆]

^{*,†,‡,§} Jérôme R. Lechien ^{*}Mons, [§]Brussels, Belgium, [†]Paris and [‡]Poitiers, France

SUMMARY: Objective. To review the current literature dedicated to the effectiveness of the diet recommendations for laryngopharyngeal reflux disease (LPRD).

Methods. Two independent investigators conducted a PubMed, Scopus, and Cochrane Library database search for studies investigating the effectiveness of anti-reflux diet in LPRD patients. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements and the Methodological Index for Non-Randomized Studies (MINORS) tool were considered for study analyses.

Results. Ten studies (868 patients) were included: two prospective controlled, four prospective uncontrolled, and four retrospective series. Diet recommendations primarily included low-fat ($n = 7$), alcohol-free ($n = 7$), low-caffeine ($n = 6$), and alkaline ($n = 6$) foods. Studies demonstrated that diet adherence led to significant symptom reduction (54%-83.3%) in untreated patients, comparable to medication effectiveness. In patients with recalcitrant symptoms despite proton pump inhibitor therapy, specific diets (alkaline, low-fat, high-protein, or gluten-free) provided significant symptom relief. All studies combining diet with medication demonstrated better outcomes than medication alone. The overall quality of studies was low with a mean MINORS of 9.5 ± 2.2 . No randomized controlled study has been conducted to compare diet versus medication.

Conclusion. Low-fat, high-protein, low-high-released sugar, and alkaline diet may appear as an effective single or combined treatment to medical therapy for patients with LPRD. Future controlled studies are needed to compare diet versus medication in LPRD populations, while considering mid- to long-term effects of diet.

Key Words: Laryngopharyngeal-Reflux-Voice-Diet-Otolaryngology-Head Neck Surgery.

INTRODUCTION

Laryngopharyngeal reflux disease (LPRD) is defined by the Dubai consensus as a disease of the upper aerodigestive tract resulting from the direct and/or indirect effects of gastroduodenal content reflux, inducing morphological and/or neurological changes in the upper aerodigestive tract.¹ Diet and autonomic nerve dysfunction have been identified as primary contributing factors of gastroesophageal and pharyngeal reflux events, leading to LPRD.²⁻⁴ From a physiological standpoint, foods and beverages may influence the gastroesophageal physiology, transient sphincter relaxation, and the related risk of pharyngeal reflux events according to their chemical composition, macronutrient profile, and physical properties.^{4,5} The current medical therapeutic approaches for LPRD may include diet and lifestyle

changes, proton pump inhibitors (PPIs), alginates, and antacids, with most medical treatment regimens being associated with diet recommendations. The anti-reflux diet recommendations are primarily based on gastroesophageal reflux disease (GERD) studies, and they are not sufficiently supported by LPR study findings.⁶ The consideration of LPRD studies rather than GERD ones is however important because both conditions substantially differ in pathophysiological and clinical findings, eg, the role of esophageal dysmotility in the disease development, the pH properties, and the nature of reflux events.⁷

This systematic review aimed to investigate the effectiveness of diet in LPRD.

METHODS

The author of the review and a university librarian conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.⁸ The criteria for considering studies were based on population, intervention, comparison, outcome, timing, and setting (PICOTS) framework.⁹

Types of studies

The literature search included randomized controlled trials, prospective studies, or retrospective chart reviews exploring the therapeutic effectiveness of anti-reflux diet in patients with suspected or confirmed LPRD. Studies were published between January 1990 and April 2023 in English-language

Accepted for publication July 21, 2025.

^{*} The authors declare that they have no relevant financial interests.

From the ^{*}Department of Surgery, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium; [†]Department of Otolaryngology - Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France; [‡]Department of Otolaryngology, Polyclinic of Poitiers, Elsan Hospital, Poitiers, France; and the [§]Department of Otolaryngology-Head & Neck Surgery, CHU Saint-Pierre (CHU de Bruxelles), Brussels, Belgium.

Address correspondence and reprint requests to: Jérôme R. Lechien, Department of Surgery, University of Mons, Mons, Belgium. E-mail:

Jerome.Lechien@umons.ac.be

Journal of Voice, Vol xx, No xx, pp. xxx-xxx

0892-1997

© 2025 The Voice Foundation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

<https://doi.org/10.1016/j.jvoice.2025.07.027>

peer-reviewed journals. Case reports, letters to the editor, comments, and basic science studies were excluded.

Population

Populations included adult patients with suspected or confirmed LPRD. Consistent with European⁷ and International Federation of Otorhinolaryngological Societies¹ consensus guidelines, the LPRD diagnosis was confirmed only for patients with more than one acid, weakly acid, or nonacid pharyngeal reflux events at the 24-hour hypopharyngeal-esophageal multichannel intraluminal impedance-pH monitoring (HEMII-pH). Subjects with more than one pharyngeal reflux events identified at the 24-hour dual- or triple-probe pH testing with pharyngeal sensor but without impedance ring were considered as acid LPRD patients. The LPRD diagnosis was suspected but not confirmed in patients with laryngopharyngeal reflux symptoms and findings, positive reflux symptom index (RSI),¹⁰ reflux symptom score (RSS),¹¹ and validated sign instruments (eg, reflux finding score (RFS),¹² reflux sign assessment (RSA)¹³), or positive diagnosis at the 24-hour Dx-pH system (oropharyngeal pH monitoring, Restech).⁷

Outcomes

The primary outcomes were the pretreatment to post treatment symptoms/findings changes in patients treated with only diet recommendations, and the composition and features of the related diet. Studies investigating diet effectiveness when combined with medication versus medication only were included as a separate study group. The secondary outcomes included demographics, gender ratio, mean/median age, and additional therapeutic outcomes (comparison with medication, duration, and follow-up). The inclusion and exclusion criteria were collected for the bias analysis.

Intervention and comparison

All types of diet were considered, including low-fat, high-protein, Mediterranean, low-high released sugar, and alkaline diets. The features related to potential comparisons of therapeutic effectiveness with other conventional treatments (eg, PPIs, alginates, and antacids) were collected. Controlled studies were defined as studies comparing pretreatment to post treatment findings of at least two groups of LPRD patients with one being treated with diet only or in combination with medication. Studies associating diet with voice therapy or alternative medicines, including Chinese herbs or acupuncture, were excluded.

Time and setting

There were no strict criteria for time and setting.

Search strategy

The two investigators independently searched the PubMed, Scopus, and Cochrane Library databases for relevant peer-reviewed publications related to the diet

therapeutic effectiveness in LPRD populations. The following keywords were used: Larynx; Laryngeal; Reflux; Laryngopharyngeal; Gastroesophageal; Diet; Food; Beverage; Change; and Outcomes. Studies reporting database abstracts, available full texts, or titles with the search terms were considered. The research findings were reviewed for relevance and the reference lists of state-of-the-art or systematic reviews were examined for additional references. The data from a 2019 systematic review were re-evaluated, included, and retrieved for the present updated review.

Bias analysis

The bias analysis was carried out with the Methodological Index for Non-Randomized Studies (MINORS) tool.¹⁴ The MINORS tool consists of several items related to the analysis of methodological points of uncontrolled or controlled studies. Each item was rated as 0 if absent or not mentioned; 1 when reported but inadequate or unclear; and 2 when reported and adequate. Among MINORS outcomes, the aim of the study was not reported (0), unclear (1), or clearly stated (2). The prospective inclusion of consecutive patients was considered as optimal (2). The endpoints were considered as fully appropriate for studies evaluating the effectiveness of diet with both validated patient-reported outcome questionnaires and finding instruments (2), partially appropriate for unvalidated symptom and/or finding scores (1), and inappropriate for symptom or finding evaluation without metric scores. According to the subjectivity in the sign assessment, an unbiased assessment was defined as a blinded evaluation of laryngoscopic examination by two independent practitioners (2). A period of 6 weeks or more was considered as adequate to observe significant symptom and finding changes (2). A period ranging from 2 to 5 weeks was considered as partially adequate (1).

RESULTS

Of the 124 identified papers, 10 studies met the inclusion criteria (868 patients) (Figure 1).^{15–24} There were two prospective controlled,^{17,22} four prospective uncontrolled,^{15,19,20,23} and four retrospective case series (Table 1).^{16,18,21,24} There were 458 (53.9%) females and 410 (46.1%) males. The mean age ranged from 30.2 to 64 years, with one study without age information.²² There was a myriad of LPRD diagnosis approaches (Table 2). The diagnosis was supported by objective approaches in five studies,^{15,17,20,24} with only two^{15,17} adhering to international consensus guidelines consisting of >1 pharyngeal reflux events at the 24-hour HEMII-pH. The diagnosis was supported by dual-probe pH monitoring in one study,²⁰ single-probe pH monitoring in another,²² and Dx-pH measurement in another one.²⁴ Other studies included suspected LPRD patients according to validated patient-reported outcomes questionnaires and/or instruments^{16,19,21} or not.^{18,23} In two studies, the authors




FIGURE 1. Chart flow.

included patients with recalcitrant LPRD symptoms and findings after PPI therapy.^{16,20} The treatment regimens are reported in Table 1. The findings of patients treated with only a diet were available in 6 studies, providing comparison with a medication group or not.^{15–20} In other studies, the diet effectiveness data were extracted from patient groups treated with medication only versus medication and diet.^{21–24}

Diet features and results

The specific diet and lifestyle recommendations are summarized in Tables 3 and 4. The most common diet recommendations included the consumption of low-fat ($n = 7$), alcohol-free ($n = 7$), low-fat dairy products ($n = 6$),

low-caffeine ($n = 6$), low-theine/mint ($n = 6$), alkaline ($n = 6$), and high-protein ($n = 5$) foods and beverages (Table 3). Among lifestyle recommendations, most authors recommended avoiding both late meals ($n = 6$) and post-meal lying down ($n = 6$), and elevation of the head of the bed ($n = 5$). Discrepancies across diet recommendations were found for eggs, small dish portion, and elevation of bed head (Table 4).

The effectiveness of diet and lifestyle recommendations was evaluated in several patient profiles with LPRD (Table 1). Three studies have investigated the diet effectiveness in untreated patients with primary LPRD symptoms and findings.^{17–19} Hamdan et al observed that fasting may lead to worsening of some LPRD symptoms,

TABLE 1.
Demographic, Clinical, and Therapeutic Outcomes

References	Design	Populations	F/M	Age	Diagnosis	Treatments	Outcomes	Results	Duration
Hránková et al, 2024 ¹⁵	Uncontrolled	36 mild CC	21/15	49	HEMII-pH	Diet	RSI reduction	Pre > post diet	3 months
	Prospective	LPRD			CC > 3 months	Diet + alginate/PPIs	Reflux episodes (n)	Pre > post diet	
Balouch et al, 2023 ¹⁶	Retrospective	81 gluten-free sLPRD	29/52	49.7	Recalcitrant sLPRD Gluten SE	Gluten-free diet	RSA-10-RSS-12 RFS/reduction in gluten-free vs no	Pre = post diet Pre > post diet 77.1% vs 43.9%	145 days
Lechien et al, 2021 ¹⁷	Prospective Controlled	50 LPRD	31/19	52.3	HEMII-pH	Diet	RSI reduction RSS and RSA	55.4% vs 25.8% Pre > post diet	6 we
Zalvan et al, 2017 ¹⁸	Retrospective	85 PPI sLPRD 99 diet sLPRD	47/38 61/38	60 57	Symptoms/signs	Diet	No-trt vs diet RSI % reduction	Diet > nothing PPI = diet	6 we
Hamdan et al, 2012 ¹⁹	Prospective	22 fasting sLPRD	0/22	30.2	RSI > 9/RFS > 7	Diet + PPIs Fasting	PPI vs diet RSI-RFS	57.1 vs 62.6 Fasting = non	1 mo
Koufman, 2011 ²⁰	Uncontrolled Prospective	20 acid LPRD	8/12	54.3	Dual-probe pH metry Recalcitrant symptoms	Diet	TC, PND, and GS RSI	Fasting > non Pre > post diet	2 we
<i>Combined Diet and Medication Studies</i>									
Lechien et al, 2019 ²¹	Retrospective	26 diet + PPIs 39 PPIs sLPRD	16/10 18/21	50.3 52.4	RSI > 13/RFS > 7	Diet + PPIs PPIs	RSI reduction Jitt%, Shim% reduction	Diet > PPI Diet > PPI	3 mo
Giacchi et al, 2000 ²³	Prospective	24 diet + PPIs/ H2 blockers sLPRD	0/24	64	Symptoms/signs	Diet + PPIs/H2 blockers	Diet adherence and symptom reduction	+ correlation	4 mo
Nanda, 2016 ²²	Uncontrolled Prospective	100 diet + PPIs sLPRD	88/112	NP	Symptoms/signs	Diet + PPIs	Symptom reduction	Diet > PPI	3 mo
Yang et al, 2018 ²⁴	Controlled Retrospective	100 PPIs sLPRD 105 sLPRD	77/28	NP 60	pH monitoring Symptoms/signs	PPIs Diet + PPIs	Symptom reduction	Diet > PPI	Diet: 2 we
		81 sLPRD	62/19	59	Dx-pH testing	PPIs/PPIs + H2 blockers			6 we

Abbreviations: CC, chronic cough; F/M, female/male; GS, globus sensation; Jitt%, percent jitter; HEMII-pH, hypopharyngeal-esophageal multichannel intraluminal impedance-pH testing; HR, high-released; mo, month(s); NP, not provided; NS, not specified; PND, postnasal drip; PPIs, proton pump inhibitors; RFS, reflux finding score; RSI, reflux symptom index; SE, sensitivity; Shim%, percent shimmer; sLPRD, suspected laryngopharyngeal reflux disease; TC, throat clearing; we, week(s).

TABLE 2.
Demographics and Clinical Summary

Outcomes	n (%)
Total number of patients	868
Gender	
Females	458 (53.9)
Males	410 (46.1)
Mean age (range, years)	30.2-64
Diagnosis methods	
HEMII-pH (> 1 pharyngeal reflux events)	2
Dual-probe pH monitoring	1
Single-probe pH monitoring	1
Dx-pH measurement	1
RSI > 9 and RFS > 7	1
RSI < 13 and RFS > 7	1
Symptoms and findings	3
LPRD patients with primary symptoms/ findings	8
LPRD patients with recalcitrant symptoms/ findings	2
Alternative treatments (control group)	
Proton pump inhibitors	5
Proton pump inhibitors and alginates/ antacids	1
Proton pump inhibitors and H2 blockers	2
Therapeutic outcomes	
RSI	5
RSS	1
RSS-12	1
RFS	2
RSA-10	1
RSA	1
Symptom/sign reduction	3
Acoustic voice parameters (%jitter, % shimmer)	1

Abbreviations: HEMII-pH, hypopharyngeal-esophageal multichannel intraluminal impedance-pH monitoring; LPRD, laryngopharyngeal reflux disease; N, number; RFS, reflux finding score; RSA, reflux sign assessment; RSI, reflux symptom index; RSS, reflux symptom score.

including throat clearing, postnasal drip, and globus sensation, while they did not find significant differences across fasting and nonfasting patients for the RSI total score.¹⁹ In a crossover observational study, our group evaluated the effectiveness of a 6-week diet on 50 patients with a demonstrated LPRD at the HEMII-pH and compared their findings to those of a control period where patients did not receive any treatment or diet. In this study, diet adherence led to a 54% symptom relief without using any medication.¹⁷

Zalvan et al retrospectively compared the findings of patients with suspected LPRD treated with PPI and reflux diet and precautions prohibiting coffee, tea, chocolate, soda, greasy, fried, fatty and spicy foods, and alcohol versus those treated with alkaline water (pH > 8.0), plant-based Mediterranean-style diet, and standard reflux precautions. The authors recommended that patients replace all beverages with alkaline water and eat a 90%-95% plant-

TABLE 3.
Diet Recommendations

Overall diet features				Detailed food and beverages recommendations															
References	Fat	HRS	Protein	Diet pH	Spicy	CB	Alcohol	RM	Butter	DP	Eggs	Caffeine	Onions	Tomato	TM	PBD	Gluten	Lactose	
Hránková et al, 2024 ¹⁵	Low	Low	High	Alkaline	-	-	-	-	Low	Low	-	-	-	-	-	-	-	-	
Balouch et al, 2023 ¹⁶	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Free	-	
Lechien et al, 2021 ¹⁷	Low	Low	High	Alkaline	Low	Low	Low	-	Low	Low	NR	Low	Low	Low	Low	High	NR	NR	
Zalvan et al, 2017 ¹⁸	Low	Low	High	Alkaline	Low	Low	Low	Low	Low	Low	-	Low	-	-	Low	High	-	-	
Hamdan et al, 2012 ¹⁹	Fasting																		
Koufman, 2011 ²⁰	Low	-	High	Alkaline	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	-	-	-	
Lechien et al, 2019 ²¹	Low	Low	High	Alkaline	Low	Low	Low	-	Low	Low	NR	Low	Low	Low	Low	High	NR	NR	
Giacchi et al, 2000 ²³	Low	-	-	-	-	Low	Low	-	-	Low	-	Low	-	-	Low	-	-	-	
Nanda, 2016 ²²	Low	-	-	-	Low	-	Low	-	-	-	-	Low	-	-	Low	-	-	-	
Yang et al, 2018 ²⁴	-	-	-	Alkaline	-	-	Low	-	-	-	-	-	-	-	-	-	-	-	

Abbreviations: CB, carbonated beverages; DP, dairy products (with milk); HRS, high-released sugar; NR, no restriction; PBD, plant-based diet; RM, red meat; TM, tea and mints.

Abbreviations: CB, carbonated beverages; DP, dairy products (with milk); HRS, high-released sugar; NR, no restriction; PBD, plant-based diet; RM, red meat; TM, tea and mints.

TABLE 4.
Lifestyle Recommendations

	Lifestyle Recommendations							
	DiP	Smok.	TC	PMS	PL	BE	LM	Hot
Hránková et al, 2024 ¹⁵	Small	-	-	-	Low	-	-	-
Balouch et al, 2023 ¹⁶	-	-	-	-	-	-	-	-
Lechien et al, 2021 ¹⁷	NR	Low	NR	Low	Low	NR	Low	-
Zalvan et al, 2017 ¹⁸	-	-	-	-	-	-	-	-
Hamdan et al, 2012 ¹⁹				-				-
Koufman, 2011 ²⁰		Low	Low	Low	Low	+	Low	-
Lechien et al, 2019 ²¹	Small	Low	Low	Low	Low	+	Low	-
Giacchi et al, 2000 ²³	-	-	-	-	Low	+	Low	-
Nanda, 2016 ²²	-	Low	-	-	Low	+	Low	Low
Yang et al, 2018 ²⁴	-	Low	Low	-	-	-	Low	-

Abbreviations: BE, bed head elevation; DiP, dish portion; LM, late meals; NR, no restriction; PL, postmeal lying down; PMS, postmeal sport; Smok., smoking; TC, tight clothing.

based diet consisting of vegetables, fruits, whole grains, and nuts with less than 5%-10% animal-based products.¹⁸ The adherence to this Mediterranean diet led to a significant reduction of RSI in 62.6% of cases, which was comparable to the intake of PPIs (57.1%).¹⁸

The comparable effectiveness of diet with medication was similarly supported by Hrankova et al in a prospective study comparing LPRD patients with mild chronic cough treated with diet only versus those with severe chronic cough treated with PPIs and alginates.¹⁵ In the group of patients with mild cough, the authors observed 30/36 (83.3%) patients with substantial symptom improvement after 12 weeks of diet and lifestyle modifications, which was comparable to the group of patients with severe LPRD-induced chronic cough treated with medications.

Patients with recalcitrant symptoms and findings despite PPI therapy were invited to adhere to a strict diet in two studies.^{16,20} In the first study, Koufman observed a significant RSI reduction after 2 weeks of alkaline, low-fat, and high-protein diet in 20 patients with recalcitrant LPRD-related symptoms.²⁰ Balouch et al investigated gluten-free diet in patients with recalcitrant symptoms and findings despite intensive medical therapy, including high-dose PPI, bedtime H2 blocker, low-acid diet, alginate, and alkaline water. In a subgroup of patients with positive gluten sensitivity on blood tests, the adherence to a gluten-free diet for 3 months led to significant reduction of laryngeal findings (RFS).¹⁶

Of the four studies investigating the effectiveness of diet and lifestyle recommendations in patients treated with LPRD medication, all authors demonstrated that adherence to diet and lifestyle changes was positively associated with a better reduction of symptoms than medication intake only (Table 1).²¹⁻²⁴

Bias analysis

The mean MINORS was 9.5 ± 2.2 (Table 5). Most studies prospectively collected clinical data, but only one included consecutive patients.¹⁷ The endpoints were fully

appropriate, associating both symptom and finding evaluations in six studies,^{15-17,19-21} while therapeutic outcomes were limited to symptoms or signs only, or were collected without using clinical instruments in others.^{18,22-24} The duration of diet is reported in Table 1. The assessment of the effectiveness of diet and lifestyle adherence was evaluated after 6 weeks in seven studies,^{15-18,21-23} which was considered as optimal regarding the literature.^{7,25} While most authors reported > 5% loss to follow-up of patients, the sample size was calculated prior to the conduction of the study in only one study.¹⁶

DISCUSSION

The cost burden associated with the diagnostic and therapeutic management of LPRD has significantly increased in the past decades. The national cost burden of diagnosing and treating LPRD in the United States of America could be 5.6 times the cost of treating GERD, with a total expenditure estimated at > \$50 billion annually.²⁶ In Europe, the lack of knowledge related to the etiological factors, clinical presentations, and therapeutic findings led to similar expenditure for public healthcare systems.²⁷ Regarding treatment, LPRD medication use increased 233%, particularly among PPIs,²⁶ while there are few studies evaluating the cost related to the management of long-term PPI and other medication use.²⁸ The investigation of the effectiveness of diet and lifestyle changes as a primary treatment of LPRD or as prevention factors is therefore mandatory to reduce both cost burden and adverse events in LPRD patients.

The findings of this review suggest that diet and lifestyle recommendations are effective as single or combined therapy with medication in patients with suspected or confirmed LPRD. Despite positive overall trends across studies, many points limit the drawing of valid conclusions.

From a methodological standpoint, most studies are retrospective chart reviews or uncontrolled prospective studies with none conducting a randomized controlled trial

TABLE 5.
Bias Analysis

References	Clearly Stated Aim	Inclusion of Consecutive Patients	Prospective Data Collection	Endpoints Appropriate to Study	Unbiased Endpoint Assessment	Follow-Up Adequate Period	<5% of Lost to Follow-Up	Sample Size Calculation	Total MINORS Score
Hránková et al, 2024 ¹⁵	2	0	2	2	2	2	0	0	10
Balouch et al, 2023 ¹⁶	2	0	0	2	2	2	0	2	10
Lechien et al, 2021 ¹⁷	2	2	2	2	2	2	2	0	14
Zalvan et al, 2017 ¹⁸	2	0	0	1	1	2	0	0	6
Hamdan et al, 2012 ¹⁹	2	0	2	2	1	1	2	0	10
Koufman et al, 2011 ²⁰	2	0	2	2	1	1	2	0	10
Lechien et al, 2019 ²¹	2	0	2	2	2	2	0	0	10
Giacchi et al, 2000 ²³	2	0	2	1	1	2	0	0	8
Nanda, 2016 ²²	2	0	2	1	1	2	2	0	10
Yang et al, 2018 ²⁴	2	0	2	1	1	1	0	0	7

comparing medication versus diet only. The lack of consideration of objective LPRD diagnosis at the 24-hour HEMII-pH is an additional limitation, which may bias the evaluation of diet effectiveness. Indeed, many prevalent conditions are associated with LPRD-like symptoms and findings, including allergy, chronic rhinosinusitis, inhaled corticosteroid-induced laryngitis, or tobacco laryngopharyngitis.^{29–32} Among studies using symptoms and signs as inclusion criteria, confounding conditions were not excluded,²² or only partially considered.^{18,23} The duration of diet is an important point in the study finding interpretation. In practice, the diet and lifestyle changes may take time for patients, leading to potential mid- to long-term benefits that are not immediately perceived by both patients and practitioners.^{18,33} This finding was strengthened in a recent study evaluating the weaning of LPRD patients with chronic PPI use.³³ Among 53 LPRD patients with a mean duration of PPI therapy of 142.3 months, Geoffroy et al observed that PPIs were successfully discontinued in 66.0% of patients who adhered to a standardized anti-reflux diet and lifestyle recommendations for at least 3 months.

From a physiopathological point of view, most diet and lifestyle recommendations were based on GERD studies, which aimed to reduce acid production and backflow of gastric content into the esophagus.³⁴ However, GERD and LPRD share distinct pathophysiological mechanisms. Contrary to GERD, LPRD is primarily an upright, daytime, gaseous and alkaline reflux disease, with less than 50% of patients having both GERD and LPRD.^{1,35–37} According to these differences, some recommendations may need revision, especially those recommending avoiding low-pH foods and beverages, and the elevation of head during nighttime.

The studies investigating the reflux event profiles of LPRD patients demonstrated that most patients with LPRD and without GERD have no nighttime pharyngeal reflux events,^{35,36} which can be attributed to the upright and gaseous pattern of reflux events.³⁸ In the same vein, the pH of pharyngeal reflux events is commonly weakly acid (4.0 to 7.0) or alkaline (> 7.0),^{35,36} and LPRD patients have a more alkaline saliva than controls,³⁹ which calls into question the need for considering alkaline foods and beverages and avoiding low-pH ones.

Pathophysiologically, the enzyme-induced inflammation of upper aerodigestive tract mucosa requires the backflow of gastroduodenal enzymes, which is related to the relaxation of both lower and upper esophageal sphincters.^{38,39} The consideration of foods and beverages associated with esophageal dysmotility and sphincter transient relaxations makes sense for establishing valid anti-reflux diet and lifestyle recommendations. A mathematical model of refluxogenic potentials of foods and beverages has been developed by our European group (Table 6), considering the available literature about the impact of foods and beverages on esophageal function.⁴⁰ Despite encouraging findings, demonstrating a significant

TABLE 6.
Recommendation Grid (Diet and Lifestyle Modifications)

Lifestyle Habits	Foods to Favor	Foods to Avoid
1. Stress control	1. <i>Meat, fish, chicken, and eggs</i>	1. <i>Meat, fish, chicken, and eggs</i>
2. Tobacco and other addiction(s) reduction	Fresh and thin fish	Fat fish, fish oil (sardines, cods, and herrings)
3. Reduction of size of meals (GERD)	Shrimps, lobster, and shellfishes	Fat chicken
4. Do not talk while eating	Chicken fillet (without skin)	High-fat meat*
5. Eat slowly	Turkey (without skin and fat)	- <i>kidneys, bacon, and ground meat,</i>
6. Avoid tight clothing (GERD only)	Duck (without skin and fat)	- <i>Pâté, tripes, and lamb</i>
7. Avoid postmeal sport (GERD only)	Low-fat meat*	- <i>Lamb chops, shoulder, or legs of lamb</i>
	- <i>Veal cutlet, pork tenderloin,</i>	- <i>Ribs, rib steak</i>
	- <i>Rindless, fatless, cooked ham</i>	- <i>Pork chops, roast, and shoulder</i>
	- <i>Steak, fillet, and striploin</i>	- <i>Foie gras</i>
	- <i>Roast veal, veal chop, and horse</i>	Delis, sausage, and salami
	*Remove fat from meat	
	Egg white	
	Other:.....	Other:.....
<i>If heartburn/acid brash (GERD only)</i>	2. <i>Dairy products</i>	2. <i>Dairy products</i>
1. Reduction of overweight	Low-fat cheese	Chocolate, ice cream, and whole milk
2. Elevating the head of the bed	Skim milk	Hard cheese, full-fat cheese
	Other:.....	- <i>Goat cheese, cheddar, and Roquefort,</i>
		- <i>Fontina, gruyere, parmesan,</i>
		<i>munster, etc</i>
		Other:.....
<i>Laryngopharyngeal reflux treatment</i>	3. <i>Cereals and Starches</i>	3. <i>Cereals and Starches</i>
Drug:	Oat, wheat, cracker, dark/whole pasta,	Chocolate cookies, peanut, and white bread,
	Whole-meal bread, brown bread,	French fries and frying
<i>To take: before-during-after</i>	Boiled potatoes, rice, brown rice, and sourdough bread	Nut, cashew, and hazelnut
	Other:.....	Other:.....
<i>Meals (circle the adequate response):</i>	4. <i>Fruit and vegetables</i>	4. <i>Fruit and vegetables</i>
-Breakfast	Agave, asparagus,	Shallot
	Banana, melon	Spicy
	Broccoli, celery, and fennel	Onion
-Lunch	Cooked mushrooms	Chilli
	Cauliflower, green beans, and ginger	Tomato (sauce or raw tomato)
-Diner	Turnip, parsley, and tofu	Raw vegetable
	Other:.....	
Drug:	<i>Vegetable preparation:</i>	
	Cooked by steaming or boiling in water	
<i>To take: before-during-after</i>	5. <i>Beverage</i>	5. <i>Beverage</i>
	Chamomile	Strong alcohol, red, and rosé wines
	Water, alkaline water	Sparkling beverage (water, soda, beer, etc)
		Coffee, tea
<i>Meals (circle the adequate response):</i>	Apple/pear juices (no sugar added)	Citrus juices (orange, grapefruit) and apple
	Melon/banana juices (no sugar added)	Other:.....
-Breakfast	Other:.....	
	6. <i>Greasy substances</i>	6. <i>Greasy substances</i>
	Olive oil	Butter, spicy oils
-Lunch	Other:.....	Sauces (mayonnaise, mustard, ketchup, etc)
		Other:.....
-Diner	7. <i>Sugar</i>	7. <i>Sugar</i>
	Honey	Sweets, viennoiseries

This grid was established for clinical practice and studies for evaluating the diet recommendations effectiveness in LPRD.

association between the refluxogenic diet score of patients and the occurrence of pharyngeal reflux events at the 24-hour HEMII-pH,⁴¹ this model is based on GERD literature, which reports conflicting data for many foods and beverages.⁴⁰ The lack of human studies evaluating the impact of commonly consumed food and beverages on esophageal and sphincter motility is therefore the primary limitation in drawing valid diet and lifestyle recommendations.

Despite substantial heterogeneity across studies, conflicting results in mechanistic studies, and the lack of LPRD-dedicated controlled studies, the findings of this review support the effectiveness of diet and lifestyle recommendations. The growing literature dedicated to the gut-laryngopharyngeal-brain axis,⁴² highlighting the importance of microbiome in human health,^{43,44} strengthens the importance of conducting future clinical and mechanistic studies investigating the short- to long-term benefit of diet in the management of LPRD. These studies should carefully consider potential confounding factors, especially autonomic nerve dysfunction, which was identified as a primary factor of resistance to anti-reflux treatments in LPRD patients.⁴⁵ Similar to some foods and beverages, autonomic nerve dysfunction has long been known to be associated with esophageal sphincter dysmotility.

CONCLUSION

Low-fat, high-protein, low-high-released sugar, and alkaline diet may appear as an effective single or combined treatment to medical therapy for patients with LPRD. The heterogeneity across studies and the lack of consideration of LPRD pathophysiology limit the drawing of valid conclusion. Future controlled studies are needed to compare diet versus medication in LPRD populations, while considering mid- to long-term effects of diet.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

None.

Author Contributions

Jérôme R. Lechien: design, acquisition of data, data analysis and interpretation, drafting, final approval, and accountability for the work; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Sponsorships

None.

References

1. Lechien JR, Vaezi MF, Chan WW, et al. The Dubai definition and diagnostic criteria of laryngopharyngeal reflux: the IFOS consensus. *Laryngoscope*. 2024;134:1614–1624. <https://doi.org/10.1002/lary.31134>.
2. Lechien JR. Anxiety and depression features in laryngopharyngeal reflux disease: a systematic review. *J Voice*. 2024. <https://doi.org/10.1016/j.jvoice.2024.12.026>. S0892-1997(24)00462-4.
3. Balouch B, Melley LE, Yeakel H, et al. Gluten sensitivity underlying resistant "Laryngopharyngeal Reflux" symptoms and signs. *J Voice*. 2023. <https://doi.org/10.1016/j.jvoice.2023.04.008>. S0892-1997(23)00131-5.
4. Nouraei SAR, Ayres L, Perring SJ. Baroreflex sensitivity in patients with laryngopharyngeal dysfunction-the overwhelmed vagus hypothesis. *JAMA Otolaryngol Head Neck Surg*. 2024;150:908–917. <https://doi.org/10.1001/jamaoto.2024.2270>.
5. Lechien JR, Bobin F, Mouawad F, et al. Development of scores assessing the refluxogenic potential of diet of patients with laryngopharyngeal reflux. *Eur Arch Otorhinolaryngol*. 2019;276:3389–3404. <https://doi.org/10.1007/s00405-019-05631-1>.
6. Min C, Park B, Sim S, Choi HG. Dietary modification for laryngopharyngeal reflux: systematic review. *J Laryngol Otol*. 2019;133:80–86. <https://doi.org/10.1017/S0022215118002256>.
7. Lechien JR, Chiesa-Estomba CM, Hans S, et al. European clinical practice guideline: managing and treating laryngopharyngeal reflux disease. *Eur Arch Otorhinolaryngol*. 2024. <https://doi.org/10.1007/s00405-024-09181-z>.
8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol*. 2021;74:790–799.
9. Thompson M, Tiwari A, Fu R, et al. A framework to facilitate the use of systematic reviews and meta-analyses in the design of primary research studies. Agency for Healthcare Research and Quality; 2012.
10. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). *J Voice*. 2002;16:274–277. [https://doi.org/10.1016/s0892-1997\(02\)00097-8](https://doi.org/10.1016/s0892-1997(02)00097-8).
11. Lechien JR, Bobin F, Muls V, et al. Validity and reliability of the reflux symptom score. *Laryngoscope*. 2020;130:E98–E107. <https://doi.org/10.1002/lary.28017>.
12. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). *Laryngoscope*. 2001;111:1313–1317. <https://doi.org/10.1097/00005537-200108000-00001>.
13. Lechien JR, Rodriguez Ruiz A, Dequanter D, et al. Validity and reliability of the reflux sign assessment. *Ann Otol Rhinol Laryngol*. 2020;129:313–325. <https://doi.org/10.1177/0003489419888947>.
14. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg*. 2003;73:712–716. <https://doi.org/10.1046/j.1445-2197.2003.02748.x>.
15. Hránková V, Balner T, Kondé A, et al. The role of an anti-reflux diet in the treatment of chronic cough caused by laryngopharyngeal reflux. *Eur Arch Otorhinolaryngol*. 2025;282:2009–2013. <https://doi.org/10.1007/s00405-025-09258-3>.
16. Balouch B, Melley LE, Yeakel H, et al. Gluten sensitivity underlying resistant "laryngopharyngeal reflux" symptoms and signs. *J Voice*. 2023. <https://doi.org/10.1016/j.jvoice.2023.04.008>. S0892-1997(23)00131-5.
17. Lechien JR, Crevier-Buchman L, Distinguin L, et al. Is diet sufficient as laryngopharyngeal reflux treatment? A cross-over observational study. *Laryngoscope*. 2022;132:1916–1923. <https://doi.org/10.1002/lary.29890>.
18. Zalvan CH, Hu S, Greenberg B, Geliebter J. A comparison of Alkaline water and mediterranean diet vs proton pump inhibition for treatment of laryngopharyngeal reflux. *JAMA Otolaryngol Head Neck Surg*. 2017;143:1023–1029. <https://doi.org/10.1001/jamaoto.2017.1454>.

19. Hamdan AL, Nassar J, Dowli A, et al. Effect of fasting on laryngopharyngeal reflux disease in male subjects. *Eur Arch Otorhinolaryngol*. 2012;269:2361–2366.
20. Koufman JA. Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications. *Ann Otol Rhinol Laryngol*. 2011;120:281–287. <https://doi.org/10.1177/000348941112000501>.
21. Lechien JR, Huet K, Khalife M, et al. Alkaline, protein, low-fat and low-acid diet in laryngopharyngeal reflux disease: our experience on 65 patients. *Clin Otolaryngol*. 2019;44:379–384. <https://doi.org/10.1111/coa.13269>.
22. Nanda MS. Role of adjuvant lifestyle modifications in patients with laryngopharyngeal reflux disease in hilly areas. *Int J Sci Study*. 2016;3:114–118.
23. Giacchi RJ, Sullivan D, Rothstein SG. Compliance with anti-reflux therapy in patients with otolaryngologic manifestations of gastroesophageal reflux disease. *Laryngoscope*. 2000;110:19–22.
24. Yang J, Dehom S, Sanders S, et al. Treating laryngopharyngeal reflux: evaluation of an anti-reflux program with comparison to medications. *Am J Otolaryngol*. 2018;39:50–55. <https://doi.org/10.1016/j.amjoto.2017.10.014>.
25. Lechien JR. Minimum effective duration of laryngopharyngeal reflux disease treatment: a prospective study. *Otolaryngol Head Neck Surg*. 2024;171:1114–1122. <https://doi.org/10.1002/ohn.878>.
26. Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. *Am J Gastroenterol*. 2013;108:905–911.
27. Lechien JR, Leclercq P, Brauner J, Pirson M. Cost burden for healthcare and patients related to the unawareness towards laryngopharyngeal reflux. *Eur Arch Otorhinolaryngol*. 2024. <https://doi.org/10.1007/s00405-024-08881-w>.
28. Verhasselt M, Rodriguez A, Dequanter D, Lechien JR. Chronic course, weaning, and awareness of patients with reflux toward proton pump inhibitor therapy. *J Voice*. 2023;37:578–585. <https://doi.org/10.1016/j.jvoice.2021.03.002>.
29. Vance D, Alnouri G, Valentino W, et al. Effects of particle size of inhaled corticosteroid on the voice. *J Voice*. 2021;35:455–457. <https://doi.org/10.1016/j.jvoice.2019.11.013>.
30. Eren E, Arslanoğlu S, Aktaş A, et al. Factors confusing the diagnosis of laryngopharyngeal reflux: the role of allergic rhinitis and inter-rater variability of laryngeal findings. *Eur Arch Otorhinolaryngol*. 2014;271:743–747. <https://doi.org/10.1007/s00405-013-2682-y>.
31. Kayali Dinc AS, Cayonu M, Sengezer T, Sahin MM. Smoking Cessation improves the symptoms and the findings of laryngeal irritation. *Ear Nose Throat J*. 2020;99:124–127. <https://doi.org/10.1177/0145561319881559>.
32. Lechien JR, Saussez S, Hopkins C. Association between laryngopharyngeal reflux, gastroesophageal reflux and recalcitrant chronic rhinosinusitis: a systematic review. *Clin Otolaryngol*. 2023;48:501–514. <https://doi.org/10.1111/coa.14047>.
33. Geoffroy L, Lechien JR. Clinical profiles and proton pump inhibitor discontinuation outcomes in laryngopharyngeal reflux disease. *Otolaryngol Head Neck Surg*. 2025. <https://doi.org/10.1002/ohn.1368>.
34. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. *Arch Intern Med*. 1991;151:448–454.
35. Salgado S, Borges LF, Cai JX, et al. Symptoms classically attributed to laryngopharyngeal reflux correlate poorly with pharyngeal reflux events on multichannel intraluminal impedance testing. *Dis Esophagus*. 2022;36:doac041. <https://doi.org/10.1093/dote/doac041>.
36. Lechien JR, Bobin F, Dapri G, et al. Hypopharyngeal-Esophageal Impedance-pH monitoring profiles of laryngopharyngeal reflux patients. *Laryngoscope*. 2021;131:268–276. <https://doi.org/10.1002/lary.28736>.
37. Lechien JR, Bobin F, Muls V, et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: clinical features and therapeutic response. *Laryngoscope*. 2020;130:E479–E489. <https://doi.org/10.1002/lary.28482>.
38. Aoun J, Muls V, Eisendrath P, Lechien JR. Diagnostic testing for laryngopharyngeal reflux disease: the role of 24-hour hypopharyngeal-esophageal multichannel intraluminal impedance-pH monitoring. *Otolaryngol Clin North Am*. 2025;58:441–449. <https://doi.org/10.1016/j.otc.2024.12.001>.
39. Lechien JR, De Marrez LG, Hans S, et al. Digestive biomarkers of laryngopharyngeal reflux: a preliminary prospective controlled study. *Otolaryngol Head Neck Surg*. 2024;170:1364–1371. <https://doi.org/10.1002/ohn.674>.
40. Lechien JR, Bobin F, Mouawad F, et al. Development of scores assessing the refluxogenic potential of diet of patients with laryngopharyngeal reflux. *Eur Arch Otorhinolaryngol*. 2019;276:3389–3404. <https://doi.org/10.1007/s00405-019-05631-1>.
41. Lechien JR, Bobin F, Muls V, et al. Patients with acid, high-fat and low-protein diet have higher laryngopharyngeal reflux episodes at the impedance-pH monitoring. *Eur Arch Otorhinolaryngol*. 2020;277:511–520. <https://doi.org/10.1007/s00405-019-05711-2>.
42. Zhao W, Zhang K, Dong WY, et al. A pharynx-to-brain axis controls pharyngeal inflammation-induced anxiety. *Proc Natl Acad Sci U S A*. 2024;121:e2312136121. <https://doi.org/10.1073/pnas.2312136121>.
43. Osadchiy V, Martin CR, Mayer EA. The Gut-Brain Axis and the microbiome: mechanisms and clinical implications. *Clin Gastroenterol Hepatol*. 2019;17:322–332. <https://doi.org/10.1016/j.cgh.2018.10.002>.
44. Alaguthevar R, Pawale AV, Murugesan B, et al. Comprehensive review of food Archaeome: exploring the understudied microbiome and health benefits of fermented foods. *Microb Pathog*. 2025;205:107718. <https://doi.org/10.1016/j.micpath.2025.107718>.
45. Yapali S, Bor S. Neural-mediated laryngopharyngeal reflux disease and the role of esophageal dysmotility. *Otolaryngol Clin North Am*. 2025;58:451–463. <https://doi.org/10.1016/j.otc.2025.01.003>.